For the quarter ended March 2024, Royalty Pharma (RPRX) reported revenue of $717 million, down 36.6% over the same period last year. EPS came in at $0.98, compared to $1.60 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $671.45 million, representing a surprise of +6.79%. The company delivered an EPS surprise of +2.08%, with the consensus EPS estimate being $0.96.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...